Project Description

Author: Alam et al.


To evaluate the efficacy of supplementation of Omega-3 fatty acid (ω-3 FA) on hepatic steatosis and liver stiffness in NAFLD patients this open label randomized clinical trial was conducted for a duration of 6 months, including 100 patients, where 50 patients (Group A) received supplementation of Omega-3 Fatty Acid (ω-3 fatty ethyl ester preparation containing ~0.465g EPA and ~0.375g DHA) + standard treatment and 50 patients (Group B) received standard therapy only. All patients were followed up at the end of 6 months by biochemical and Transient Elastography. All methods were done in accordance with the Declaration of Helsinki. Improvement of CAP parameter and stiffness of liver were the primary endpoints.. At inclusion, the demographics, biochemical tests, glucose control of both groups were comparable. Beneficial changes in alanine aminotransferase (ALT ), aspartate aminotransferase (AST) and gamma glutamyl transferase favoured the intervention group. At the end of the treatment, ω-3 FA showed a beneficial effect on hepatic steatosis measured by controlled attenuation parameter (CAP) in the intervention group where CAP reduced from 305.9 ±38.8 dB/m to 284.4 ±47.1 dB/m, (p=0.005). Moreover, the average changes in CAP was significantly better in intervention group compared to control (21.6 ± 51.3 dB/m vs -9.1 ± 43.3 dB/m, p=0.002). However, no beneficial change was seen in liver stiffness of patients in any group (p=0.873). Therefore, intervention with ω-3 FA improves hepatic steatosis and liver enzyme levels in NAFLD except liver stifness.

Key words: Non-alcoholic steatohepatitis, NASH, Omega 3 Fatty Acid, liver stiffness, steatosis

Status: Ongoing

Full text link: Not available